I appreciate your brief indulgence, Madam Chair. I will bring it back, I promise you, and I was about to. That was only to say that the pandemic left us with the lesson about pharmaceutical sovereignty.
We were hearing from articulate witnesses who are experts in their fields. I saw colleagues around the table engaged and seized with the issue, but all of a sudden, this motion, which had nothing to do with the second part of the meeting, as I understand it, came up. It could have come up at any other time. There is, I believe—of course there is; every committee has one—a steering committee where that matter could have been addressed.